{"id":"artesunate-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate acts primarily through its endoperoxide bridge, which is cleaved by heme iron in malaria parasites to generate cytotoxic reactive oxygen species that damage parasite proteins and DNA. Beyond antimalarial activity, artesunate has demonstrated immunomodulatory effects and potential anti-cancer properties through induction of apoptosis and differentiation in cancer cells, making it a candidate for both infectious disease and oncology applications.","oneSentence":"Artesunate is an artemisinin derivative that generates reactive oxygen species to kill malaria parasites and has immunomodulatory and anti-cancer properties.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:47.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria (treatment and severe malaria)"},{"name":"Cancer (investigational, various solid tumors)"}]},"trialDetails":[{"nctId":"NCT06923592","phase":"PHASE3","title":"Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2025-05-12","conditions":"Malaria Vivax, Malaria Falciparum, Plasmodium Vivax","enrollment":19200},{"nctId":"NCT07470424","phase":"PHASE1","title":"A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-06-01","conditions":"Malaria","enrollment":24},{"nctId":"NCT06967519","phase":"PHASE4","title":"OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-18","conditions":"Malaria, Hiv","enrollment":380},{"nctId":"NCT06806956","phase":"","title":"Severe Malaria in Remote Areas- Closing the Evidence Gap","status":"ENROLLING_BY_INVITATION","sponsor":"Tropical Diseases Research Centre, Zambia","startDate":"2024-03-10","conditions":"Severe Malaria","enrollment":2016},{"nctId":"NCT06872112","phase":"PHASE1","title":"A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"Joseph C. Wu","startDate":"2026-01-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":15},{"nctId":"NCT04675931","phase":"PHASE2","title":"To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-07","conditions":"Severe Malaria","enrollment":254},{"nctId":"NCT06519994","phase":"PHASE2","title":"Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-01-22","conditions":"Human Immunodeficiency Virus, Human Papillomavirus, Cervical Precancer","enrollment":120},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1680},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":"Plasmodium Vivax Malaria, Malaria","enrollment":7530},{"nctId":"NCT06853184","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Artesunate","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2025-08-01","conditions":"CMV Infection","enrollment":90},{"nctId":"NCT04098744","phase":"PHASE2","title":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2020-09-09","conditions":"CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia","enrollment":78},{"nctId":"NCT07022743","phase":"PHASE2","title":"Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Obafemi Awolowo University","startDate":"2025-07-01","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":75},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":"Malaria","enrollment":870},{"nctId":"NCT06263582","phase":"PHASE1","title":"Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-05-29","conditions":"Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3, Cervix; Intraepithelial Neoplasia, Grade I","enrollment":12},{"nctId":"NCT06075264","phase":"PHASE2","title":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2023-12-06","conditions":"Vulvar Diseases, HPV Infection, Vulvar HSIL","enrollment":27},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT06206564","phase":"PHASE2","title":"Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2024-01-12","conditions":"Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection","enrollment":48},{"nctId":"NCT04706130","phase":"PHASE4","title":"Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-04-15","conditions":"Vivax Malaria","enrollment":160},{"nctId":"NCT06173206","phase":"PHASE3","title":"Parasite Clearance and Protection from Infection (PCPI) in Cameroon","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2024-06-10","conditions":"Malaria","enrollment":902},{"nctId":"NCT06166498","phase":"PHASE3","title":"Parasite Clearance and Protection From Infection (PCPI) in Zambia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2024-07-24","conditions":"Malaria","enrollment":600},{"nctId":"NCT06294912","phase":"PHASE1","title":"A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":"Malaria","enrollment":16},{"nctId":"NCT06555809","phase":"","title":"Evaluation of Artesunate in Infants Being Treated for Severe Malaria","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2024-10-06","conditions":"Malaria","enrollment":15},{"nctId":"NCT03792516","phase":"PHASE1","title":"Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-04-17","conditions":"Vulvar Dysplasia, HPV-Related Vulvar Intraepithelial Neoplasia, Preinvasive Vulvar Disease","enrollment":15},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT04921930","phase":"PHASE1, PHASE2","title":"Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2022-05-06","conditions":"Friedreich Ataxia","enrollment":20},{"nctId":"NCT06472258","phase":"NA","title":"Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2023-03-01","conditions":"Malaria","enrollment":104},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":"Plasmodium Falciparum, Malaria, Uncomplicated Malaria","enrollment":352},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT05140278","phase":"PHASE2","title":"Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-07-18","conditions":"Severe Malaria","enrollment":200},{"nctId":"NCT00616304","phase":"PHASE2","title":"Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria","status":"SUSPENDED","sponsor":"Menzies School of Health Research","startDate":"2008-02","conditions":"Severe Falciparum Malaria","enrollment":8},{"nctId":"NCT01868438","phase":"PHASE1","title":"Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2013-05","conditions":"Malaria","enrollment":60},{"nctId":"NCT01523002","phase":"PHASE1","title":"Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2012-01","conditions":"Malaria","enrollment":56},{"nctId":"NCT04330690","phase":"PHASE3","title":"Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-03-18","conditions":"COVID-19","enrollment":2900},{"nctId":"NCT04713631","phase":"PHASE2","title":"Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease","status":"UNKNOWN","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2021-01-21","conditions":"Crohn's Disease","enrollment":40},{"nctId":"NCT01640587","phase":"NA","title":"Compare the Effectiveness Between Existing Treatment and New Treatment","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2013-11","conditions":"P. Falciparum Malaria","enrollment":76},{"nctId":"NCT00331136","phase":"PHASE2","title":"Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2006-06","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":60},{"nctId":"NCT05192265","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":"Malaria Fever, Plasmodium Falciparum Malaria, Uncomplicated Malaria","enrollment":172},{"nctId":"NCT05273242","phase":"PHASE4","title":"Add-on Study on WHO Solidarity Trial Plus for COVID-19 in Nepal","status":"UNKNOWN","sponsor":"Nepal Health Research Council","startDate":"2021-12-06","conditions":"COVID-19","enrollment":400},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511},{"nctId":"NCT04618523","phase":"PHASE4","title":"Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2020-10-26","conditions":"Malaria","enrollment":1117},{"nctId":"NCT05223933","phase":"NA","title":"Proactive Community Case Management (Pro-CCM) in Rural Madagascar","status":"COMPLETED","sponsor":"Institut Pasteur de Madagascar","startDate":"2016-12-12","conditions":"Malaria, Case Management","enrollment":1000},{"nctId":"NCT04368910","phase":"PHASE3","title":"Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria","status":"TERMINATED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09-06","conditions":"Malaria","enrollment":30},{"nctId":"NCT04374019","phase":"PHASE2","title":"Novel Agents for Treatment of High-risk COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Susanne Arnold","startDate":"2020-05-01","conditions":"COVID, Sars-CoV2","enrollment":13},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT03100045","phase":"PHASE1","title":"Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-04-20","conditions":"HPV-Related Anal Intraepithelial Neoplasia, AIN2/3, Artesunate","enrollment":18},{"nctId":"NCT00440999","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-03","conditions":"Malaria","enrollment":456},{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Malaria","enrollment":1272},{"nctId":"NCT01594931","phase":"PHASE2","title":"Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2005-07","conditions":"Plasmodium Falciparum Malaria","enrollment":477},{"nctId":"NCT00403260","phase":"PHASE3","title":"Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Falciparum Malaria","enrollment":1271},{"nctId":"NCT00356824","phase":"","title":"Relationship Between HIV and Malaria in Ugandan Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-11","conditions":"HIV Infections, Malaria","enrollment":300},{"nctId":"NCT04701606","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients","status":"UNKNOWN","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2021-03-29","conditions":"Covid19","enrollment":402},{"nctId":"NCT00297882","phase":"PHASE3","title":"Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2006-07","conditions":"Malaria","enrollment":816},{"nctId":"NCT03083847","phase":"PHASE1","title":"Dose Escalation PfSPZ-CVac","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":"Malaria","enrollment":55},{"nctId":"NCT04877626","phase":"PHASE4","title":"Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2008-09","conditions":"P. Falciparum Malaria","enrollment":210},{"nctId":"NCT02084602","phase":"PHASE4","title":"Assessment of Artesunate/Mefloquine in the Peruvian Amazon","status":"COMPLETED","sponsor":"Instituto Nacional de Salud. Peru","startDate":"2014-06-18","conditions":"Malaria, Falciparum","enrollment":45},{"nctId":"NCT02354534","phase":"PHASE1","title":"Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-02","conditions":"Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)","enrollment":30},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT03893097","phase":"PHASE3","title":"Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2019-10-14","conditions":"Schistosoma Haematobium, Schistosoma Mansoni","enrollment":726},{"nctId":"NCT04829695","phase":"PHASE4","title":"Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon","status":"UNKNOWN","sponsor":"University of Yaounde 1","startDate":"2021-04-05","conditions":"Falciparum Malaria","enrollment":184},{"nctId":"NCT04565184","phase":"PHASE4","title":"Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2019-05-09","conditions":"Malaria,Falciparum","enrollment":242},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":"Malaria, Burkina Faso","enrollment":1050},{"nctId":"NCT02653898","phase":"PHASE4","title":"Malaria Elimination Pilot Study in Military Forces in Cambodia","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2016-01","conditions":"Malaria, Parasitic Diseases","enrollment":1050},{"nctId":"NCT03726593","phase":"PHASE4","title":"Drug Combinations of Atovaquone-Proguanil (AP) With ACT","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2018-10-04","conditions":"Plasmodium Falciparum Malaria (Drug Resistant)","enrollment":252},{"nctId":"NCT00123552","phase":"PHASE3","title":"Longitudinal Antimalarial Combinations in Uganda","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-11","conditions":"Malaria","enrollment":601},{"nctId":"NCT02671175","phase":"PHASE3","title":"Post-discharge Malaria Chemoprevention(PMC) Study","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2016-05-20","conditions":"Malaria, Severe Anemia","enrollment":1049},{"nctId":"NCT04370977","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2018-03-21","conditions":"Malaria","enrollment":630},{"nctId":"NCT02851108","phase":"PHASE2","title":"Methylene Blue Against Falciparum Malaria in Burkina Faso","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2016-10","conditions":"Malaria, Falciparum","enrollment":100},{"nctId":"NCT04049916","phase":"PHASE2, PHASE3","title":"Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-09-12","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT04228315","phase":"NA","title":"Biomarkers of P. Vivax Relapse","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2019-11-19","conditions":"Malaria, Vivax Malaria, Relapse","enrollment":100},{"nctId":"NCT02996695","phase":"PHASE1","title":"Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-04-06","conditions":"Plasmodium Falciparum Infection","enrollment":62},{"nctId":"NCT02612545","phase":"PHASE1","title":"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-20","conditions":"Acute Falciparum Malaria","enrollment":216},{"nctId":"NCT00298610","phase":"PHASE2","title":"Safety and Efficacy Study of IV Artesunate to Treat Malaria","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2006-03","conditions":"Malaria","enrollment":30},{"nctId":"NCT03814616","phase":"PHASE2","title":"Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections","status":"UNKNOWN","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2018-10-03","conditions":"Malaria,Falciparum","enrollment":300},{"nctId":"NCT02663700","phase":"PHASE1","title":"Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-07","conditions":"Plasmodium Falciparum Infection","enrollment":112},{"nctId":"NCT03773536","phase":"PHASE4","title":"Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2017-05-09","conditions":"Plasmodium Falciparum Malaria","enrollment":146},{"nctId":"NCT03768908","phase":"PHASE4","title":"Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2005-01-05","conditions":"Plasmodium Falciparum Malaria","enrollment":359},{"nctId":"NCT03764527","phase":"PHASE4","title":"Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2002-11-01","conditions":"Plasmodium Falciparum Malaria","enrollment":408},{"nctId":"NCT00292942","phase":"PHASE1","title":"Study of the Safety of Intravenous Artesunate","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2006-06-12","conditions":"Malaria, Malaria, Cerebral","enrollment":26},{"nctId":"NCT01845701","phase":"PHASE3","title":"Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2010-03","conditions":"Malaria","enrollment":720},{"nctId":"NCT02389439","phase":"PHASE2","title":"Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-03-01","conditions":"Malaria, Falciparum","enrollment":123},{"nctId":"NCT00936767","phase":"PHASE2, PHASE3","title":"Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia","status":"WITHDRAWN","sponsor":"University of Oxford","startDate":"2010-10","conditions":"Uncomplicated Falciparum Malaria","enrollment":""},{"nctId":"NCT00682578","phase":"PHASE3","title":"A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-07","conditions":"Uncomplicated Falciparum Malaria, Vivax Malaria","enrollment":1086},{"nctId":"NCT00493363","phase":"NA","title":"Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-06","conditions":"Falciparum Malaria","enrollment":40},{"nctId":"NCT01955382","phase":"PHASE2","title":"Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09","conditions":"Malaria, Severe Malaria","enrollment":70},{"nctId":"NCT01967472","phase":"NA","title":"Adherence to Antimalarial Drugs in Sierra Leone","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-09-16","conditions":"Malaria","enrollment":1145},{"nctId":"NCT02940756","phase":"PHASE4","title":"Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2017-03-15","conditions":"Malaria","enrollment":1615},{"nctId":"NCT01976780","phase":"PHASE4","title":"In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy","status":"COMPLETED","sponsor":"Global Emerging Infections Surveillance and Response System","startDate":"2013-06","conditions":"Malaria","enrollment":118},{"nctId":"NCT02592408","phase":"PHASE4","title":"A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2015-11","conditions":"Malaria","enrollment":320},{"nctId":"NCT00158548","phase":"PHASE3","title":"ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2001-06","conditions":"Malaria, Falciparum Malaria, Vivax Malaria","enrollment":650},{"nctId":"NCT00146731","phase":"PHASE3","title":"A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2004-01","conditions":"Malaria","enrollment":310},{"nctId":"NCT00132548","phase":"PHASE3","title":"A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2004-06","conditions":"Malaria","enrollment":2200},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT00380146","phase":"NA","title":"Pharmacokinetics, Efficacy, Gametocyte Carriage, Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment in Pregnant Women","status":"COMPLETED","sponsor":"Professor Karen I Barnes","startDate":"2006-09","conditions":"Malaria","enrollment":31},{"nctId":"NCT00432367","phase":"PHASE3","title":"Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2007-02","conditions":"Malaria, Anaemia, Pregnancy","enrollment":3333},{"nctId":"NCT00694694","phase":"PHASE3","title":"Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2008-06","conditions":"Malaria","enrollment":261},{"nctId":"NCT02242799","phase":"PHASE1","title":"Dolutegravir Interactions With Artemisinin-based Combination Therapies","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2015-06","conditions":"Malaria, HIV","enrollment":46},{"nctId":"NCT00852423","phase":"PHASE3","title":"Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2010-06","conditions":"Malaria in Pregnancy","enrollment":3428},{"nctId":"NCT02052323","phase":"PHASE4","title":"Harmonized AS/MQ Efficacy Study - Thailand","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2013-10","conditions":"Malaria","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Artesunate 2","genericName":"Artesunate 2","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate is an artemisinin derivative that generates reactive oxygen species to kill malaria parasites and has immunomodulatory and anti-cancer properties. Used for Malaria (treatment and severe malaria), Cancer (investigational, various solid tumors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}